COVID-19: Vaccines and Therapeutics
Pfizer announced additional phase 2/3 clinical trial data for its COVID-19 oral antiviral treatment, indicating the pill’s high degree of effectiveness in reducing high-risk patients’ risks of hospitalization or death from SARS-CoV-2 infection.
The U.S. Court of Appeals for the Eighth Circuit denied a stay pending appeal of the Missouri district court’s preliminary injunction enjoining the Centers for Medicare & Medicaid Services vaccine mandate in the 10 states that are part of that lawsuit.
The holiday season is a good motivator to become fully vaccinated, say clinicians at Mount Sinai Health System in New York, a state where the omicron variant has spread.
National poll reveals 40% of parents said their health care provider has the biggest influence on their decision to vaccinate their kids.
The Food and Drug Administration authorized using the combination monoclonal antibody therapy Evusheld to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components.
The Food and Drug Administration announced the widely anticipated expansion of Pfizer’s COVID-19 vaccine emergency use authorization to allow booster doses for 16- and 17-year-olds.
Pfizer released preliminary laboratory findings on its COVID-19 vaccine’s effectiveness against the SARS-CoV-2 Omicron variant, offering an early look at the two, distinct dosing regiments currently authorized in the U.S.
The U.S. Court of Appeals for the Eleventh Circuit issued its opinion explaining why it denied Florida’s motion for an injunction pending appeal.
The Food and Drug Administration authorized administering bamlanivimab and etesivimab together to treat or prevent COVID-19 in all pediatric patients exposed to or testing positive for the virus who are at high risk for progressing to severe disease.
Growing concerns over the omicron COVID-19 variant ahead of holiday gatherings result in long lines at vaccine clinics in Massachusetts.